SGLT2 inhibitor for protein in urine from lupus or vasculitis
Part of Heart & circulation, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests a medication called an SGLT2 inhibitor (usually used for diabetes, but being studied for kidney disease) to see if it can reduce the amount of protein leaking into the urine in people with chronic kidney disease from lupus nephritis or ANCA-associated vasculitis, which may help protect the kidneys.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have kidney disease (stage 1 to 3) caused by lupus nephritis or ANCA-associated vasculitis.
- Your kidney disease must be stable — not in an active flare.
- You cannot have type 1 or type 2 diabetes.
- You must not have frequent urinary tract infections or known allergy/intolerance to SGLT2 inhibitor drugs.
- Your kidney function (eGFR) must be 30 or higher.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a diabetes drug called dapagliflozin can help people with active lupus nephritis by reducing protein in the urine and preserving kidney function. It is given in addition to standard treatments.
This trial tests if empagliflozin, a medicine used for diabetes, can help protect kidney function in people with active lupus nephritis. You may be eligible if you have a lupus kidney flare with significant protein in your urine.
This trial tests a new treatment for people with lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and protect kidney function.
This study tests if an SGLT2 inhibitor can help protect kidney function in people who have lupus nephritis (kidney inflammation caused by lupus) and chronic kidney disease (CKD). The goal is to see if this medicine can slow down further kidney damage.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This study tests whether SGLT2 inhibitors (a type of diabetes drug that also helps kidneys) can help patients with acute kidney disease. It may be an option if you have diabetes or chronic kidney disease along with acute kidney problems.
Hear when a new Lupus Nephritis (LN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.